<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04110587</url>
  </required_header>
  <id_info>
    <org_study_id>DUROLANE2013</org_study_id>
    <nct_id>NCT04110587</nct_id>
  </id_info>
  <brief_title>Hyaluronic Acid Evaluation as Adjuvant to Temporomandibular Joint Arthroscopy</brief_title>
  <official_title>Hyaluronic Acid Evaluation as Adjuvant to Temporomandibular Joint Arthroscopy in Wilkes Stages</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Universidad Complutense de Madrid</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Fundación de Investigación Biomédica - Hospital Universitario de La Princesa</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Zambon SpA</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Universidad Complutense de Madrid</source>
  <brief_summary>
    <textblock>
      This study evaluates the addition of hyaluronic acid to temporomandibular joint arthroscopy
      in the treatment of internal derangements in adults. A participants group will receive
      temporomandibular joint arthroscopy plus hyaluronic acid, while the other group will receive
      temporomandibular joint arthroscopy. Hypothesis: hyaluronic acid as an adjunct in
      temporomandibular joint arthroscopic surgery provides additional benefits in clinical and
      radiological outcomes in temporomandibular joint internal derangements.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 10, 2013</start_date>
  <completion_date type="Actual">July 9, 2019</completion_date>
  <primary_completion_date type="Actual">July 9, 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
    <masking_description>Treatment allocation was concealed from participants and examiner (using sealed and numbered opaque envelopes by the research coordinator), and the data analyst (by encoded data).</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Mean Change from Baseline in Pain Scores on the Visual Analog Scale at 3,6,9 and 12 Months</measure>
    <time_frame>From enrollment to end of study at 12 Months. Baseline, Month 3, Month 6, Month 9, Month 12.</time_frame>
    <description>Visual Analog Scale 0 to 10. Higher values represent a worse outcome.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean Change from Baseline in Maximal Oral Opening Scores (mm) at 3,6,9 and 12 Months</measure>
    <time_frame>From enrollment to end of study at 12 Months. Baseline, Month 3, Month 6, Month 9, Month 12.</time_frame>
    <description>measured from edge of upper central incisor to edge of lower antagonist incisor. Range scale 0 to 60 (mm). Higher values represent a better outcome.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean Change from Baseline in Oral Health Impact Profile-14 Spanish Version (OHIP-14sp) questionnaire Scores at 6 and 12 Months</measure>
    <time_frame>From enrollment to end of study at 12 Months. Baseline, Month 6, Month 12.</time_frame>
    <description>OHIP-14sp questionnaire total average score to measure Oral Health-Related Quality of Life. Range scale 0 to 56. Higher values represent a worse outcome. Total average score is calculated by adding the score of each question and dividing by 14</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Treatment Related Adverse Events</measure>
    <time_frame>From intervention to end of study at 12 Months. During procedure or immediately after intervention, Month 3, Month 6, Month 9, Month 12.</time_frame>
    <description>any adverse response to the intervention</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Symptoms Duration Mean (Months)</measure>
    <time_frame>At baseline</time_frame>
    <description>symptoms duration mean reported by the participants</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with chondromalacia</measure>
    <time_frame>During intervention</time_frame>
    <description>arthroscopic finding</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with synovitis</measure>
    <time_frame>During intervention</time_frame>
    <description>arthroscopic finding</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Irrigation Volume Mean (cc)</measure>
    <time_frame>During intervention</time_frame>
    <description>average irrigation fluid used during intervention</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Occlusal Stabilization Splint</measure>
    <time_frame>From enrollment to end of study at 12 Months. Baseline, Month 3, Month 6, Month 9, Month 12.</time_frame>
    <description>stabilization splint use reported by the participant</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Osteophyte by magnetic resonance imaging</measure>
    <time_frame>At baseline and Month 12.</time_frame>
    <description>radiographic finding in jaw condyle</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with joint surfaces flattening by magnetic resonance imaging</measure>
    <time_frame>At baseline and Month 12</time_frame>
    <description>radiographic finding in jaw condyle or temporal bone</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Subchondral Geode by magnetic resonance imaging</measure>
    <time_frame>At baseline and Month 12</time_frame>
    <description>radiographic finding in jaw condyle</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disc Position by magnetic resonance imaging</measure>
    <time_frame>At baseline and Month 12</time_frame>
    <description>No Displacement, Disc Displacement with Reduction, Disc Displacement without Reduction</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with pain in masseter muscle by digital palpation</measure>
    <time_frame>From enrollment to end of study at 12 Months. Baseline, Month 3, Month 6, Month 9, Month 12.</time_frame>
    <description>pain reported by the participant</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with pain in Temporal muscle by digital palpation</measure>
    <time_frame>From enrollment to end of study at 12 Months. Baseline, Month 3, Month 6, Month 9, Month 12.</time_frame>
    <description>pain reported by the participant</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with pain in Medial Pterygoid Muscle by digital palpation</measure>
    <time_frame>From enrollment to end of study at 12 Months. Baseline, Month 3, Month 6, Month 9, Month 12.</time_frame>
    <description>pain reported by the participant</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with pain in digastric Muscle by digital palpation</measure>
    <time_frame>From enrollment to end of study at 12 Months. Baseline, Month 3, Month 6, Month 9, Month 12.</time_frame>
    <description>pain reported by the participant</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with pain in Genihyoid Muscle by digital palpation</measure>
    <time_frame>From enrollment to end of study at 12 Months. Baseline, Month 3, Month 6, Month 9, Month 12.</time_frame>
    <description>pain reported by the participant</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with pain in Mylohyoid Muscle by digital palpation</measure>
    <time_frame>From enrollment to end of study at 12 Months. Baseline, Month 3, Month 6, Month 9, Month 12.</time_frame>
    <description>pain reported by the participant</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">54</enrollment>
  <condition>Temporomandibular Joint Disc Displacement</condition>
  <condition>Temporomandibular Joint Disorders</condition>
  <arm_group>
    <arm_group_label>arthroscopy</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Temporomandibular joint arthroscopy is performed under general anesthesia by the same expert temporomandibular joint arthroscopy surgeon. Lysis and Lavage is performed in the upper joint space in all cases. Ringer's lactate is use as irrigation fluid. All participants receive Amoxicillin / Clavulanic Acid, 1g I.V. and Dexamethasone, 4 mg I.V. (Intraoperative); as well as Amoxicillin / clavulanic acid, 500/125 mg / 8h / 5 days by mouth; Diclofenac 100 mg / 12h / 5 days by mouth; and Metamizol 575 mg / 8h by mouth (Post-operatively). Soft diet and a home exercise program are implemented in all patients after 24 hours post-operative.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>arthroscopy plus hyaluronic Acid</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Temporomandibular joint arthroscopy is performed under general anesthesia by the same expert temporomandibular joint arthroscopy surgeon. Lysis and Lavage is performed in the upper joint space in all cases. Ringer's lactate is use as irrigation fluid. All participants receive Amoxicillin / Clavulanic Acid, 1g I.V. and Dexamethasone, 4 mg I.V. (Intraoperative); as well as Amoxicillin / clavulanic acid, 500/125 mg / 8h / 5 days by mouth; Diclofenac 100 mg / 12h / 5 days by mouth; and Metamizol 575 mg / 8h by mouth (Post-operatively). Soft diet and a home exercise program are implemented in all patients after 24 hours post-operative. An hyaluronic acid injection of 1 mL (Durolane®, 20 mg / mL, Zambon, Barcelona, Spain) at the end of arthroscopy that was only performed in this arm.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Hyaluronic Acid</intervention_name>
    <description>1 mL Hyaluronic Acid Injection (20 mg/mL, 7000 KDa) at the end of arthroscopy .</description>
    <arm_group_label>arthroscopy plus hyaluronic Acid</arm_group_label>
    <other_name>Sodium Hyaluronate</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Temporomandibular Joint Arthroscopy</intervention_name>
    <description>Lysis and Lavage</description>
    <arm_group_label>arthroscopy</arm_group_label>
    <arm_group_label>arthroscopy plus hyaluronic Acid</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Antibiotic therapy</intervention_name>
    <description>Amoxicillin / Clavulanic Acid, 1g I.V. (Intraoperative); as well as Amoxicillin / clavulanic acid, 500/125 mg / 8h / 5 days by mouth (Post-operative).</description>
    <arm_group_label>arthroscopy</arm_group_label>
    <arm_group_label>arthroscopy plus hyaluronic Acid</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>corticosteroid</intervention_name>
    <description>Dexamethasone, 4 mg I.V. (Intraoperative)</description>
    <arm_group_label>arthroscopy</arm_group_label>
    <arm_group_label>arthroscopy plus hyaluronic Acid</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Antiinflammatories</intervention_name>
    <description>Diclofenac 100 mg / 12h / 5 days by mouth (Post-operatively).</description>
    <arm_group_label>arthroscopy</arm_group_label>
    <arm_group_label>arthroscopy plus hyaluronic Acid</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Analgesics</intervention_name>
    <description>Metamizol 575 mg / 8h by mouth (Post-operatively)</description>
    <arm_group_label>arthroscopy</arm_group_label>
    <arm_group_label>arthroscopy plus hyaluronic Acid</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Exercise program</intervention_name>
    <description>Home exercise program</description>
    <arm_group_label>arthroscopy</arm_group_label>
    <arm_group_label>arthroscopy plus hyaluronic Acid</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of temporomandibular joint internal derangements in Wilkes stages III and IV
             by magnetic resonance imaging

          -  Limitation of maximum oral opening or duplication of joint pain by palpation

          -  lack of response to conservative therapies

        Exclusion Criteria:

          -  Any degenerative systemic disease of muscular or joint involvement (rheumatoid
             arthritis, etc.)

          -  Previous temporomandibular joint surgical treatment: arthrocentesis, arthroscopy or
             open surgery

          -  Infection in Temporomandibular Joint or in puncture site

          -  Hyaluronic acid or corticosteroids injection in Temporomandibular Joint in previous 6
             months

          -  Pregnant or breastfeeding women

          -  Participants who refuse to complete the treatment or unavailable to complete the
             follow-up
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jorge Cano Sánchez</last_name>
    <role>Study Director</role>
    <affiliation>Complutense University of Madrid</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Julian Campo Trapero</last_name>
    <role>Study Director</role>
    <affiliation>Complutense University of Madrid</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mario Fernando Muñoz Guerra</last_name>
    <role>Study Director</role>
    <affiliation>Fundación de Investigación Biomédica - Hospital Universitario de La Princesa</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Oscar Gabriel Castaño Joaqui</last_name>
    <role>Principal Investigator</role>
    <affiliation>Complutense University of Madrid</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital Universitario de La Princesa</name>
      <address>
        <city>Madrid</city>
        <zip>28006</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <reference>
    <citation>Montero-Martín J, Bravo-Pérez M, Albaladejo-Martínez A, Hernández-Martín LA, Rosel-Gallardo EM. Validation the Oral Health Impact Profile (OHIP-14sp) for adults in Spain. Med Oral Patol Oral Cir Bucal. 2009 Jan 1;14(1):E44-50.</citation>
    <PMID>19114956</PMID>
  </reference>
  <reference>
    <citation>Slade GD, Spencer AJ. Development and evaluation of the Oral Health Impact Profile. Community Dent Health. 1994 Mar;11(1):3-11.</citation>
    <PMID>8193981</PMID>
  </reference>
  <reference>
    <citation>Shi Z, Guo C, Awad M. Hyaluronate for temporomandibular joint disorders. Cochrane Database Syst Rev. 2003;(1):CD002970. Review. Update in: Cochrane Database Syst Rev. 2013;10:CD002970.</citation>
    <PMID>12535445</PMID>
  </reference>
  <reference>
    <citation>Wilkes CH. Internal derangements of the temporomandibular joint. Pathological variations. Arch Otolaryngol Head Neck Surg. 1989 Apr;115(4):469-77.</citation>
    <PMID>2923691</PMID>
  </reference>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>September 23, 2019</study_first_submitted>
  <study_first_submitted_qc>September 28, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 1, 2019</study_first_posted>
  <last_update_submitted>September 28, 2019</last_update_submitted>
  <last_update_submitted_qc>September 28, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 1, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>hyaluronic acid</keyword>
  <keyword>temporomandibular joint arthroscopy</keyword>
  <keyword>internal derangements</keyword>
  <keyword>disc displacement</keyword>
  <keyword>temporomandibular disorders</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Joint Diseases</mesh_term>
    <mesh_term>Temporomandibular Joint Disorders</mesh_term>
    <mesh_term>Temporomandibular Joint Dysfunction Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anti-Bacterial Agents</mesh_term>
    <mesh_term>Hyaluronic Acid</mesh_term>
    <mesh_term>Analgesics</mesh_term>
    <mesh_term>Anti-Inflammatory Agents</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

